novo nordisk semaglutide lawsuit Says It's Suing Hims to Halt Obesity Drug Copycats Novo Nordisk A/S (NVO) Securities

While patients with minimal alcohol use (up to 20/30 g/d in women/men) were enrolled in the ESSENCE trial, those with higher alcohol consumption [ie, in the MetALD (metabolic dysfunction and alcohol-associated liver disease) range] were excluded

Some people achieve dramatic appetite suppression at lower doses, while others require higher doses to reach the same effect

You do not need to wait for a months-long appointment at a specialists office

Ro published a real-world study in Obesity journal on December 10, 2025

The analysis revealed four common adverse events across both genders: nausea, weight loss, vomiting, and diarrhea

Hazard ratio (HR) and 95% confidence intervals (CI) of incident and recurrent CUD were calculated for 12-month follow-up by comparing propensity-score matched patient cohorts